Fisher Asset Management LLC Grows Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Fisher Asset Management LLC increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.6% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 276,822 shares of the biopharmaceutical company’s stock after buying an additional 1,587 shares during the quarter. Fisher Asset Management LLC’s holdings in Halozyme Therapeutics were worth $10,231,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in HALO. Parkside Financial Bank & Trust acquired a new stake in Halozyme Therapeutics in the 4th quarter valued at $64,000. Headlands Technologies LLC increased its stake in shares of Halozyme Therapeutics by 1,068.2% during the fourth quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 1,613 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth about $196,000. Cetera Trust Company N.A purchased a new position in Halozyme Therapeutics in the 4th quarter valued at about $208,000. Finally, First Trust Direct Indexing L.P. acquired a new stake in Halozyme Therapeutics in the 4th quarter worth about $209,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. JMP Securities reiterated a “market outperform” rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, February 21st. The Goldman Sachs Group dropped their price objective on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a report on Thursday, January 18th. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research note on Tuesday, April 30th. TheStreet cut Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research note on Monday, January 22nd. Finally, Benchmark reissued a “buy” rating and set a $50.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $53.29.

Halozyme Therapeutics Stock Up 2.4 %

Shares of NASDAQ:HALO opened at $40.86 on Tuesday. The firm has a market cap of $5.19 billion, a price-to-earnings ratio of 19.37, a PEG ratio of 0.47 and a beta of 1.26. Halozyme Therapeutics, Inc. has a 12-month low of $29.85 and a 12-month high of $45.00. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89. The stock’s 50-day moving average price is $40.01 and its two-hundred day moving average price is $37.94.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The company had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. On average, research analysts forecast that Halozyme Therapeutics, Inc. will post 3.43 EPS for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total value of $416,400.00. Following the completion of the sale, the senior vice president now directly owns 156,558 shares in the company, valued at approximately $6,519,075.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 30,000 shares of company stock worth $1,196,800 over the last quarter. 2.70% of the stock is owned by corporate insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.